In the TCGA dataset, we found that CD209 was expressed in various cancer types, while its mRNA abundance was highest in sarcoma (SARC) (Figure 2A), whereas the protein level of CD209 was most enriched in head and neck cancer (Figure 2B). This evidence concerns the gene CD209 and head and neck cancer.